Re: NMP22 is a sensitive, cost-effective test in patients at risk for bladder cancer
- PMID: 10411075
- DOI: 10.1016/s0022-5347(05)68609-0
Re: NMP22 is a sensitive, cost-effective test in patients at risk for bladder cancer
Comment on
-
NMP22 is a sensitive, cost-effective test in patients at risk for bladder cancer.J Urol. 1999 Jan;161(1):62-5. J Urol. 1999. PMID: 10037369 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous